Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	5,099	$464.59	620,576
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	5,463	$463.54	625,675
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	3,317	$462.43	631,138
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	1,159	$461.79	634,455
Feb 24, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	118,123	$420.17	517,799
Feb 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	172,723	$399.66	925,209
Dec 18, 2017	YANCOPOULOS GEORGE Director, President & CSO	Director, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	257,850	$386.90	422,762
Dec 13, 2017	YANCOPOULOS GEORGE Director, President & CSO	Director, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	11,124	$385.08	775,662
Dec 13, 2017	YANCOPOULOS GEORGE Director, President & CSO	Director, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	95,050	$385.08	680,612
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,429	$380.09	686,571

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media